Femasys (FEMY) received approval from the New Zealand Medicines and Medical Devices Safety Authority for its FemBloc Permanent Birth Control. This approval confirms that FemBloc meets the country’s standards for safety, quality, and effectiveness, and represents an important milestone in Femasys’ global expansion strategy to make this revolutionary non-surgical permanent birth control option available to women worldwide.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY: